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Mutational heterogeneity in genes causative of dominantly inherited disorders represents a signiﬁcant barrier for development of ther-
apies directed towards correction of the primary genetic defect. To circumvent the mutational heterogeneity present in rhodopsin- (RHO-)
linked autosomal dominant Retinitis Pigmentosa (adRP), a strategy involving suppression and replacement of RHO has been adopted.
RNA interference- (RNAi-) mediated suppression of RHO has been explored as has the generation of an RNAi-resistant replacement
gene using the degeneracy of the genetic code. Additionally, the functional equivalence of codon-modiﬁed replacement genes has been
demonstrated in a transgenic animal (RHO-M). Suppression and replacement, while exempliﬁed by adRP, may also be relevant to many
other dominantly inherited diseases with the hallmark of mutational heterogeneity.
 2007 Elsevier Ltd. All rights reserved.
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Inherited diseases frequently are more diverse than
might be predicted from their clinical presentation. In the
case of some Mendelian disorders, many diﬀerent muta-
tions within the same gene can give rise to or predispose
an individual to a given disease. The presence of such
immense heterogeneity underlying a clinical pathology is
clearly demonstrated by Retinitis Pigmentosa (RP [MIM
+180380]), a condition primarily involving photoreceptor
cell loss (Farrar, Kenna, & Humphries, 2002). In addition,
over 40 diﬀerent genes have been implicated in RP. In one
of these genes alone, the human rhodopsin gene (RHO
[GenBank Accession No. NM_000539.2]), over 150 muta-
tions leading to autosomal dominant RP (adRP) have been0042-6989/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.visres.2007.08.014
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1 These authors contributed equally to this work.characterised to date (Retinal Information Network
Database).
Mutational heterogeneity represents a signiﬁcant barrier
to the development of therapies for many inherited dis-
eases. To address this problem in disorders such as RHO-
linked RP, a mutation-independent suppression and
replacement strategy has been proposed (Cashman, Bink-
ley, & Kumar-Singh, 2005; Hauswirth & Lewin, 2000; Mil-
lington-Ward et al., 1997; O’Reilly et al., 2007). In essence,
the approach involves suppression of both mutant and wild
type alleles of a target gene and concomitant provision of a
replacement gene which has been sequence-modiﬁed to
evade suppression (Gorbatyuk, Justilien, Liu, Hauswirth,
& Lewin, 2007; Kiang et al., 2005; Palﬁ et al., 2006). In
the current study RNA interference (RNAi), (Elbashir
et al., 2001; Fire et al., 1998) has been used to achieve
potent suppression of expression of RHO. However, other
suppression agents such as ribozymes or antisense technol-
ogies could also be utilised. In parallel with suppression, a
Table 2
Codon usage in RHO and rCC-RHO
RHO L Y V T V
RHO CTC TAC GTC ACC GTC
Codon usage in RHO 10 17 15 15 15
rCC-RHO L Y V T V
rCC-RHO CTG TAT GTG ACG GTG
Codon usage in rCC-RHO 15 2 13 6 13
Numbers refer to the frequency of use of endogeneous codons versus those
which have been altered in rCC-RHO.
Fig. 1. Diagrammatic representation of the construct used to generate the
RHO-M mouse. Replacement RHO (rCC-RHO) incorporating the RHO
cDNA with ﬁve/four altered nucleotides at wobble positions within the
siC and siCC target sites, respectively, and the RHO polyadenylation
signal was driven by a Rho promoter (RhoP). Intron 9 of the hypoxan-
thine–guanine phosphoribosyl transferase (HPRT) gene was included 3 0 of
the rCC-RHO gene to facilitate transgene expression. Restriction enzyme
sites and sizes are indicated.
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genetic code can be employed to generate a codon-modiﬁed
replacement gene in which the nucleotide sequence over the
target site for suppression diﬀers suﬃciently from the wild
type sequence such that transcripts from this gene are
resistant to suppression but encode wild type protein. In
principle, suppression and replacement circumvents the
mutational heterogeneity present in RHO-linked adRP
and a single therapeutic should be applicable to any adRP
patient with a RHO mutation.
Codon usage has been analysed for multiple genes from
many species and has been found to inﬂuence gene expres-
sion patterns (Ren et al., 2007; Shabalina, Ogurtsov, &
Spiridonov, 2006). It would be preferable when engineering
codon-modiﬁed replacement genes to minimise changes in
codon usage where possible. While the altered nucleotides
introduced into replacement genes at wobble positions
encode the same amino acids, it is possible that such base
changes may inﬂuence features such as three dimensional
structure or half-life of transcripts.
To explore the feasibility of suppression and replace-
ment therapy for RHO-linked adRP, aspects of both com-
ponents have been addressed in the current study. Small
interfering RNAs (siRNAs) targeting RHO have been gen-
erated and RNAi-mediated suppression evaluated. Subse-
quently, the resistance of a codon-modiﬁed RHO
replacement gene to RNAi-mediated suppression has been
explored. In addition, transgenic mice expressing this
replacement gene have been generated (RHO-M). Trans-
genic mice were mated with Rho knockout mice (Rho/),
(Humphries et al., 1997) and the functional equivalence
of the codon-modiﬁed RHO to rhodopsin investigated.
2. Materials and methods
2.1. siRNAs and RHO constructs
RHO- (NM_000539.2) targeting siRNAs, siCC, siC, siEGFP, and
siNT (O’Reilly et al., 2007), and a replacement (r) RHO cDNA,
rCC-RHO, containing four and ﬁve nucleotide changes at the siCC and
siC target sites, respectively, have been described (Table 1). rCC-RHO
was driven by the CMV (pcDNA3.1, Invitrogen), human Ubiquitin
C (UBC [GenBank Accession No. NM_021009] (pUB6-V5-His, Invitro-
gen Ltd., Crawley, UK) or a 3.8 kb fragment of the mouse Rho promoter
(Mouse Genome Informatics Accession No. MGI:97914).
2.2. RHO replacement mouse model, RHO-M
A transgenic mouse model was generated which expresses a replace-
ment human RHO cDNA (rCC-RHO) designed to avoid suppression by
siCC and siC which target codons 59–63 of RHO. Exploiting the degener-Table 1
siCC and siC RHO target sites
Target site
CC CTCTACGTCACCGTCCAGCACAAGAA
C CTCTACGTCACCGTCCAGCACAA
Underlined sequences indicate siRNA, siCC (codons for amino acids 61–67 of
overlap. Nucleotides in bold are those altered in rCC-RHO.acy of the genetic code, PCR-directed mutagenesis was used to generate
rCC-RHO which has altered codons 59–63 (Tables 1 and 2 and Fig. 1)
and includes the RHO polyadenylation signal. Care was taken to maintain
a similar pattern of codon usage to RHO. 3.8 kb fragment of the Rho pro-
moter was used to express rCC-RHO and intron 9 of hypoxantine–guan-
ine phosphoribosyltransferase (HPRT [GenBank Accession No.
NM_000194]) was cloned downstream. The construct was microinjected
into male pro-nuclei of fertilised eggs to generate transgenic progeny. Four
founder animals, identiﬁed by Southern blotting, yielded four individual
transgenic mouse lines (O’Reilly et al., 2007). One line was evaluated in
this study.
2.3. Experimental animals, immunocytochemistry, and
electroretinography
One- and three-month-old wild type Rho+/+, NHR+/ Rho/
expressing a normal RHO transgene (McNally et al., 1992; Olsson
et al., 1992), RHO-M+/ Rho/ (O’Reilly et al., 2007) and Rho/
mice (Humphries et al., 1997) were used in the study. All animals were
on a 129 background. Rho immunocytochemistry, ﬂuorescent microscopy
(Kiang et al., 2005) and electroretinography (ERG) were performed as
described (O’Reilly et al., 2007). On this occasion gold wire electrodes
were used rather than contact lens electrodes previously described.
2.4. Cell culture, RNA islolation and quantitative real time
RT-PCR (qPCR)
CMV promoter-driven wild type RHO or rCC-RHO constructs and
siCC, siC, or siNT were co-transfected in quadruplicate into HeLa cells
(ATCC no. CCL-2), (Millington-Ward et al., 2004) and RNA was isolated
24 h post-transfection (Palﬁ et al. 2006). RNA from retinas was isolatedReplacement sequence
CTGTATGTGACGGTGCAGCACAAGAA
CTGTATGTGACGGTGCAGCACAAGAA
RHO), and siC (codons for amino acids 59–66 of RHO), target sites which
388 M. O’Reilly et al. / Vision Research 48 (2008) 386–391using the RNeasy Mini Kit (Qiagen Ltd. Crawley, UK). RHO mRNA
expression levels were assessed by qPCR as described (O’Reilly et al.,
2007). qPCR reactions were typically performed twice in triplicate. To
compare levels of endogenous mouse Rho to human RHO transgene
expression qPCR with the following primer pair, which amplify both
mouse and human rhodopsin mRNA, was performed:
• F: AGCAGCAGGAGTCAGCCACC;
• R: CCGAAGTTGGAGCCCTGGTG.2.5. Statistical analysis
Data sets for a given construct were pooled, averaged and standard
deviation (SD) values calculated. Statistical signiﬁcance of diﬀerences
between control and target data sets were determined by ANOVA using
least signiﬁcant diﬀerence post hoc test (Data Desk 6.1, Data Descriptions
Inc., New York, USA); diﬀerences with p < .05 were considered statisti-
cally signiﬁcant.3. Results
Previously, siRNA-mediated suppression of RHO has
been explored (O’Reilly et al., 2007). Further work up of
an siRNA molecule (siCC) targeting RHO has been under-
taken in the current study and both potency of RNAi-med-
iated suppression and resistance of a modiﬁed replacement
gene (rCC-RHO, Tables 1 and 2) to suppression evaluated
in HeLa cells. siRNAs (comprising both RHO-targeting
and non-targeting controls) were co-transfected with a
plasmid expressing the wild type RHO cDNA. Levels of
expression achieved in cells transfected with siCC and siC
were evaluated using qPCR and compared to those in cells
transfected with the non-targeting control siRNA, siNT.
Signiﬁcant suppression of the target gene by siCC (62%;
p < .01, Fig. 2A) and siC (63%; p < .01; data not shown)
was obtained at the mRNA level. RHO immunocytochem-
istry supported these ﬁndings as siCC suppressed RHO sig-Fig. 2. Suppression of RHO in HeLa cells. A replacement RHO sequence,
Ubiquitin C promoter (UBCP-rCC-RHO) was generated with altered dege
co-transfected in quadruplicate with each of the above two rCC-RHO constr
RHO mRNA levels were evaluated by qPCR (A). Error bars represent SD va
Alexa Fluor 568-labelled Rho immunocytochemistry (red). Nuclei counter-stain
control. Scale bar represents 30 lm.niﬁcantly (Fig. 2D) while no suppression was observed
with siEGFP (Fig. 2B) or siNT (Fig. 2C).
In addition to suppression, the possible resistance of a
human replacement gene rCC-RHO which contains
sequence-modiﬁcations at degenerate positions over the
target site for siCC and siC (Table 1) was explored. It is
notable that in generating rCC-RHO, care was taken to
minimise disruption to codon usage patterns for the
RHO gene (Table 2). Where possible, synonymous codons
with similar usage frequencies were employed. To explore
the resistance of rCC-RHO to siCC- and siC-mediated sup-
pression in cells, the replacement gene was expressed from
either the Ubiquitine C (UBC) or the CMV promoter.
siCC-mediated suppression of rCC-RHO was eliminated
irrespective of the level of expression of the replacement
gene from either promoter (Fig. 2A). In contrast, siC sup-
pressed rCC-RHO by 53% (data not shown).
Although the introduction of synonomous codons in a
modiﬁed replacement gene serves to alter the nucleotide
sequence whilst conserving amino acid sequence, it was
important to explore the functionality of the modiﬁed
rCC-RHO and encoded protein in vivo. To address this
issue, a transgenic mouse RHO-M expressing rCC-RHO
was generated (Fig. 1). 3.8 kb fragment of the Rho pro-
moter was used to drive expression of rCC-RHO. RHO-M
mice were bred with Rho/ mice, the latter displaying a
severe form of retinal degeneration (Humphries et al.,
1997). Subsequently, doubly transgenic mice (RHO-M+/
Rho/) were evaluated by retinal histology and ERG.
Retinal histology was undertaken on Rho/,
RHO-M+/ Rho/, and Rho+/+ mice at one and three
months of age. In RHO-M+/ Rho/ mice a single copy
of the rCC-RHO transgene (Fig. 3C and D) was found to
be suﬃcient to compensate for the absense of Rho in
Rho/mice (Fig. 3A and B). Notably, outer nuclear layer
(ONL) thickness ofRHO-M+/Rho/mice (Fig. 3C andrCC-RHO, driven by either a CMV promoter (CMVP-rCC-RHO) or a
nerate nucleotides at the siCC target site. HeLa cells were transiently
ucts and siNT, siEGFP, or siCC. Following transfection, rCC-RHO and
lues, * represents p < .01. Alternatively, suppression was evaluated using
ing with DAPI (blue). B, siEGFP; C, siNT; D, siCC; and E, untransfected
Fig. 3. Histology of RHO-M mouse retina. Ten micrometer cryosections
from 1- (A, C, and E) and 3- (B, D, and F)month-oldRho/,RHO-M+/
Rho/ and wild type Rho+/+ mice were labelled by Rho immunocyto-
chemistry (Cy3; red) using RHO 4D2 antibody (Kiang et al., 2005; Li,
Snyder, Olsson, & Dryja, 1996) and DAPI nuclear counterstaining (blue).
Retinas of 1- and 3-month-old RHO-M (C and D) and wild type Rho+/+
animals (E andF) display normal inner and outer segments with strongRho
labelling in the latter and very similar inner and outer nuclear, and ganglion
cell layers. Note that Rho labelling is more extensive in the outer nuclear
layer of RHO-Mmice (C and D) than in the Rho+/+ animals (E and F). In
contrast, outer segments never develop in Rho/ mice (A and B) and
retinas lack Rho immunolabelling. Moreover, inner segments, present at
one month of age (A), have degenerated completely by 3 months (B). While
inner and outer nuclear layers appear nearly normal in 1-month-old
Rho/mice (A), by three months, the outer nuclear layer consists of only
a single row of nuclei (B). OS, rod outer segments; IS, rod inner segments;
ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell
layer. Scale bar represents 50 lm.
Fig. 4. ERG analysis of RHO-M mouse. One- and three-month-old (1 and
analysed by ERG. Representative rod-isolated (a) and maximal ERG response
months between Rho+/+ and RHO-M+/ Rho/ are due to natural variat
M. O’Reilly et al. / Vision Research 48 (2008) 386–391 389D) was comparable to that ofRho+/+mice (Fig. 3E and F).
Similarly the retinal histology ofRHO-M+/Rho/mice
andNHR+/Rho/mice, the latter carrying a single copy
of a wild type RHO gene and displaying a wild type pheno-
type (McNally et al., 1992; Olsson et al., 1992), was found
to be comparable (data not shown). Also, while the Rho/
mouse shows no Rho immunolabelling and does not
elaborate rod outer segments (OS, Fig. 3A and B),
RHO-M+/ Rho / and Rho+/+ mice show strong
RHO immunolabelling in the OS (Fig. 3C and D) and outer
segments are clearly visible. Note thatRHO-M+/Rho/
mice display increased RHO labelling in the ONL compared
to Rho+/+ mice.
In addition to retinal histology, retinal function was
assessed by ERG. Notably, both the rod-isolated
(Fig. 4a) and the maximal, combined rod and cone
responses (Fig. 4b) in RHO-M+/ Rho/ mice were of
comparable amplitudes to those from Rho+/+ and
NHR+/ Rho/ mice (data not shown for the latter).
The rCC-RHO transgene restored the normal ERG, absent
in Rho/ mice in RHO-M+/ Rho/ mice (Fig. 4).
Note that while a rod-derived ERG can never be detected
in Rho/ mice, at one month of age there is a small
but measurable maximal ERG response due to cone func-
tion. Diﬀerences in ERG amplitude between 1- and
3-month-old RHO-M+/ Rho/ and Rho+/+ mice rep-
resent normal variations. While clearly the results
described above suggest that rCC-RHO is functionally
equivalent to Rho and RHO (present in NHR animals, data
not shown), it was of interest to explore levels of the rCC-
RHO cDNA transgene expression (Fig. 5). A comparison
of levels of rhodopsin expression between RHO-M+/
Rho/, NHR+/ Rho/, and Rho+/+ mice using
qPCR with a common primer pair, revealed that rCC-
RHO in RHO-M+/ Rho/ mice is expressed at approx-
imately 75% of the level of that in NHR+/ Rho/ or
Rho+/+ mice (p < .01, Fig. 5). The level of RHO expres-3 m) Rho/, RHO-M+/ Rho/ and wild type Rho+/+ mice were
s (b) are given. Note that diﬀerences in ERG amplitudes at one and three
ion. Scale units are 50 ms and 500 mV.
Fig. 5. Rhodopsin mRNA expression in wild type Rho+/+, NHR+/
Rho/, and RHO-M+/ Rho/ mice. Levels of endogeneous mouse
Rho mRNA in Rho+/+ mice were compared to levels of human RHO
mRNA in transgenic NHR+/ Rho/ and RHO-M+/ Rho/ mice
by qPCR. Error bars represent SD values. * represents p < .01.
390 M. O’Reilly et al. / Vision Research 48 (2008) 386–391sion in NHR+/ Rho/ mice and Rho expression in wild
type Rho+/+ mice was found to be statistically the same.
In summary, the data obtained from the study suggest that
codon-modiﬁed RHO replacement genes can be engineered
using the degeneracy of the genetic code to be refractory to
RNAi-mediated suppression while being functionally
equivalent to wild type rhodopsin.4. Discussion
Understanding of the molecular pathogenesis of genetic
conditions has served to highlight that many diseases are
highly heterogeneous at the molecular level. Novel thera-
peutic approaches for such disorders, which are gene-inde-
pendent, are being developed by attempting to modulate
secondary features associated with the disease pathology.
These include modulating apoptosis which is frequently
prematurely invoked in neurodegenerative conditions
including RP (Marigo, 2007). Similarly, therapies based
on provision of neurotrophic factors or anti-oxidants are
being considered (Thanos & Emerich, 2005). However,
given knowledge of the underlying genetic etiologies of
many conditions, it would be valuable to target therapies
towards correction of the primary genetic lesion. In this
regard, mutational heterogeneity inherent in even single-
gene disorders such as RHO-linked adRP with over 150
diﬀerent mutations represents a signiﬁcant challenge.
Given this scenario, a two-component therapeutic strat-
egy to circumvent such mutational heterogeneity, termed
suppression and replacement, has been explored involving
RNAi-mediated suppression used in parallel with provision
of a codon-modifed replacement gene. While the principle
is easy to annunciate, achieving potent suppression in con-
junction with optimal levels of replacement may be chal-
lenging. Hence, elements of suppression and replacement
have been explored in the current study. Potent RNAi-
mediated suppression of RHO expression has been
achieved in cell culture at both the mRNA and protein lev-
els (Fig. 2), as has the generation of an RNAi-resistantcodon-modiﬁed RHO replacement gene, rCC-RHO
(Fig. 1). While siCC with four nucleotide mismatches did
not suppress rCC-RHO signiﬁcantly, siC with ﬁve mis-
matches suppressed rCC-RHO by 53% (Table 1, data not
shown). This highlights the need for caution when design-
ing therapeutic suppression and replacement constructs.
Although conservative changes were introduced into
rCC-RHO to ensure that transcripts from this gene are
refractory to RNAi-mediated suppression by siCC
(Table 1), it was of value to probe in depth whether a
codon-modiﬁed RHO replacement cDNA was functionally
equivalent to the endogenous Rho gene. RHO-M+/ mice
generated for this purpose were bred onto a Rho/ back-
ground and detailed histological and ERG analyses under-
taken. Notably, the severe retinopathy present in Rho/
mice is absent in RHO-M+/ Rho/ mice due to the
presence of a single copy of the rCC-RHO transgene as
evaluated by retinal histology and ERG (Figs. 3 and 4).
It is of note that rCC-RHO is expressed in the ONL of
adult RHO-M+/ Rho/ retinas. Similarly, Rho+/+
mice express Rho in the ONL at early stages of develop-
ment (typically up to 3 weeks). This indicates that rCC-
RHO has not an identical transport pattern to wild type
Rho in older animals, possibly due to the promoter used
or a lack of intronic sequences. Evaluation of rCC-RHO
transgene expression levels using qPCR indicated that the
transgene was expressed at approximately 75% of the level
of both Rho in wild type mice and of the RHO transgene in
NHR+/ Rho/ mice (Fig. 5).
Given the mutational heterogeneity inherent in many
dominantly inherited conditions, approaches such as that
described in the current study will be required when
attempting to correct the primary genetic defect. Indeed,
suppression and replacement has been suggested as a
potential therapeutic approach for other dominantly inher-
ited conditions with the hallmark of mutational heteroge-
neity, for example, motor neuron disease (MIM #147450)
(Xia et al., 2005) and osteogenesis imperfecta (MIM
#166200), (Millington-Ward et al., 2004). In the current
study, aspects of both the suppression and the replacement
components for RHO-linked adRP therapies have been
explored. Results demonstrate the feasibility both of potent
RNAi-mediated suppression of RHO and generation of
RNAi-resistant codon-modiﬁed replacement RHO genes
which are functionally equivalent to the wild type gene.
5. Web resources
Accession numbers and URLs for data presented herein
are as follows: ATCC, http://www.atcc.org/ (for HeLa cells
[Accession No. CCL-2]), GenBank, http://www.ncbi.
nlm.nih.gov/Genbank/ (for RHO [Accession No. NM_
000539.2] HPRT [Accession No. NM_000194], UBC
[Accession No. NM_021009]), Mouse Genome Informat-
ics, http://www.informatics.jax.org/ (for Rho [Accession
No. MGI:97914]), Online Mendelian Inheritance in Man
(OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for RP,
M. O’Reilly et al. / Vision Research 48 (2008) 386–391 391type I collagen-linked osteogenesis imperfecta, motor neu-
ron disease), Retinal Information Network database,
http://www.sph.uth.tmc.edu/Retnet/.
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